Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Photos from a project conducted in collaboration with photographer Pearl Gan at EOCRU in Jakarta, Indonesia were published last week in the Lancet. The See Malaria in Asia Project aims to raise public awareness of malaria as a serious health problem for the region by telling the human story of Asia’s invisible malaria burden.

CTMGH logo for News

Photos from a project conducted in collaboration with photographer Pearl Gan at EOCRU in Jakarta, Indonesia were published last week in the Lancet. The See Malaria in Asia Project aims to raise public awareness of malaria as a serious health problem for the region by telling the human story of Asia’s invisible malaria burden.

Most malaria in Asia occurs among the rural poor, who do not yet live among the benefits of the profound economic progress that the region has seen. These populations are often “invisible”, not only in an epidemiological sense but also in social terms. And therefore communities who are engaged with the global malaria problem do not see all those affected by malaria in Asia.

Funded by the Wellcome Trust, this photography project aims to engage the public with exhibitions later in the year in Jakarta, Singapore, Phnomh Penh and Ho Chi Minh City. While working on the project, photographer Pearl Gan visited remote communities where endemic malaria causes illness and deaths.  EOCRU Director Prof Kevin Baird says, “Pearl Gan captures much in her art – humanity, dignity, suffering. Her lens exposes the reality of the isolation and poverty that give malaria such freedom of harm and constraint of human development.”

Read more »

Similar stories

World’s largest clinical trial for COVID-19 treatments expands internationally

OCGHR Research

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) Trial, the world’s largest clinical trial for COVID-19 treatments, has now expanded internationally with Indonesia and Nepal among the first countries to join. The first patients have been recruited to RECOVERY International.

Tocilizumab reduces deaths in patients hospitalised with COVID-19

OCGHR Research

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial has demonstrated that tocilizumab, an anti-inflammatory treatment, reduces the risk of death when given to hospitalised patients with severe COVID-19. The study also showed that tocilizumab shortens the time until patients are successfully discharged from hospital and reduces the need for a mechanical ventilator.

Evidence supports WHO recommendation for primaquine combined with ACTs to block Plasmodium falciparum transmission

OCGHR Publication Research

Evidence from a new study, initiated by the Primaquine Roll Out Group and conducted at WWARN, supports the World Health Organization (WHO) recommendation for use of 0.25mg/kg dose of primaquine (PQ) combined with artemisinin-based combination therapies (ACT) to block Plasmodium falciparum transmission.

Baricitinib to be investigated as a possible treatment for COVID-19 in the RECOVERY trial

OCGHR Research

Baricitinib – an anti-inflammatory treatment for rheumatoid arthritis– is being investigated in the RECOVERY trial, the world’s largest clinical trial of treatments for patients hospitalised with COVID-19, taking place in 177 hospital sites across the UK and with over 33,000 patients recruited so far. As an anti-inflammatory, baricitinib may block the signalling activity of cytokine molecules which contribute to the hyper-inflammatory state seen in severe COVID-19. It is thought that baricitinib may act also have some anti-viral activity. The other treatments currently being investigated in the RECOVERY trial are Regeneron’s antibody cocktail, Aspirin and Colchicine.

Indonesia’s decision to prioritise COVID-19 vaccination to citizens aged 18-59 years old questionable

EOCRU MORU OUCRU

The Indonesian government policy to exclude the elderly in the first phase of the COVID-19 vaccination program could hinder the vaccine’s impact in lowering mortality rates. COVID-19 mortality rates in Indonesia, the highest in Southeast Asia, are dominated by those in the 60 years and above age bracket. In this article published in The Conversation, Kartika Saraswati and fellow DPhil students elaborate how, by prioritising vaccination for elderly, Indonesia may optimally reduce the hospital burden and COVID-19 deaths amidst a limited vaccine supply during the first vaccination phase.

Community and Public Engagement at KWTRP

KWTRP Public Engagement

KWTRP initial community and public engagement strategy was developed in 2005 with three goals: build understanding and trust between researchers and communities, enhance ethical conduct of research, and disseminate research findings to promote uptake into policy. Our programme has since developed and now includes engagement with media, radio programme, media engagement workshops, various meetings and forums, and a fully-fledged school engagement programme that was awarded the 2019 Oxford VC Public Engagement with Research Award.